<code id='7EEDB29ADE'></code><style id='7EEDB29ADE'></style>
    • <acronym id='7EEDB29ADE'></acronym>
      <center id='7EEDB29ADE'><center id='7EEDB29ADE'><tfoot id='7EEDB29ADE'></tfoot></center><abbr id='7EEDB29ADE'><dir id='7EEDB29ADE'><tfoot id='7EEDB29ADE'></tfoot><noframes id='7EEDB29ADE'>

    • <optgroup id='7EEDB29ADE'><strike id='7EEDB29ADE'><sup id='7EEDB29ADE'></sup></strike><code id='7EEDB29ADE'></code></optgroup>
        1. <b id='7EEDB29ADE'><label id='7EEDB29ADE'><select id='7EEDB29ADE'><dt id='7EEDB29ADE'><span id='7EEDB29ADE'></span></dt></select></label></b><u id='7EEDB29ADE'></u>
          <i id='7EEDB29ADE'><strike id='7EEDB29ADE'><tt id='7EEDB29ADE'><pre id='7EEDB29ADE'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:comprehensive    Page View:6
          Influenza A virions
          F. A. Murphy/CDC

          Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

          Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

          advertisement

          The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In